CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia
15. November 2024 08:45 ET
|
CERo Therapeutics Holdings, Inc.
SOUTH SAN FRANCISCO, Calif, Nov. 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of...
Envoy Medical Receives FDA Approval To Initiate Pivotal Clinical Study for Breakthrough Hearing Device
01. November 2024 08:00 ET
|
Envoy Medical, Inc
The Acclaim® Fully Implanted Cochlear Implant is differentiated from existing cochlear implants and may offer new option for hearing loss patients WHITE BEAR LAKE, Minnesota, Nov. 01, 2024 (GLOBE...
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec®, an Innovative Diagnostic Solution for Fallopian Tube Check
09. September 2024 08:30 ET
|
Femasys Inc.
ATLANTA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of...
BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family
29. August 2024 08:30 ET
|
BioCardia, Inc.
SUNNYVALE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
New to The Street Announces its Five Corporate Interviews, Airing Episode 591 on the Fox Business Network, Tonight Monday, August 26, 2024, at 10:30 PM PT
26. August 2024 09:15 ET
|
FMW Media Works Corp
New to The Street Announces its Five Corporate Interviews, Airing Episode 591 on the Fox Business Network, Tonight Monday, August 26, 2024, at 10:30 PM PT
FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment
21. August 2024 07:00 ET
|
BioCardia, Inc.
BioCardia announced today that the FDA has approved an important protocol amendment for the CardiAMP Heart Failure II Trial, its confirmatory Phase 3 trial
New to The Street TV Announces Episode 583, Five Riveting Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Saturday, August 10, 2024, at 6:30 PM ET
09. August 2024 09:30 ET
|
FMW Media Works Corp
New to The Street TV Announces Episode 583, Five Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Saturday, August 10, 2024
BioCardia Submits for FDA Approval of Morph® DNA™ Steerable Introducer Product Family
30. Juli 2024 07:00 ET
|
BioCardia, Inc.
BioCardia, Inc., today reported it has submitted a 510(k) for approval of its patented Morph® DNA™ Steerable Introducer Sheath with the FDA.
Truveta announces support for regulatory submissions to the FDA and global regulatory authorities
18. Juni 2024 11:13 ET
|
Truveta
BELLEVUE, Wash., June 18, 2024 (GLOBE NEWSWIRE) -- Today, Truveta announced regulatory and audit capabilities to support its customers for real-world evidence (RWE) submissions to the Food and Drug...
Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024
13. März 2024 09:00 ET
|
Femasys Inc.
-- CEO Kathy Lee-Sepsick and Chief Medical Officer James Liu to Join Jones Trading Analyst Catherine Novack in a Conversation on Current Treatment Options in Infertility Including FemaSeed® at 1PM ET...